Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

Active:	No
Cancer Type:	Leukemia Multiple Myeloma	NCT ID:	NCT04887259
Trial Phases:	Phase I Phase II	Protocol IDs:	LV2020-001 (primary) NCI-2022-06213
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Lava Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT04887259

Summary

A phase 1/2a, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in
patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma
(MM), or Acute Myeloid Leukemia (AML).

Objectives

An open-label, phase 1/2a dose escalation trial with disease-specific expansion cohorts to
evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and
preliminary anti-tumor activity of LAVA-051 in patients with relapsed or refractory CLL, MM,
or AML.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.